FDA ‘Confident’ That Interchangeable Insulin Will Be Available After March 2020

Drug Industry Daily
A A
Approved NDAs for certain biological products will be deemed to be biologics licenses under new FDA policies beginning March 2020, allowing the products to compete under the biosimilars pathway and potentially lower drug costs.

To View This Article:

Login

Subscribe To Drug Industry Daily